Adrenergic alpha-Antagonists
"Adrenergic alpha-Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
| Descriptor ID |
D000317
|
| MeSH Number(s) |
D27.505.519.625.050.200.100 D27.505.696.577.050.200.100
|
| Concept/Terms |
Adrenergic alpha-Antagonists- Adrenergic alpha-Antagonists
- Adrenergic alpha Antagonists
- alpha-Antagonists, Adrenergic
- Adrenergic alpha-Receptor Blockaders
- Adrenergic alpha Receptor Blockaders
- Blockaders, Adrenergic alpha-Receptor
- alpha-Receptor Blockaders, Adrenergic
- alpha-Adrenergic Blocking Agents
- Agents, alpha-Adrenergic Blocking
- Blocking Agents, alpha-Adrenergic
- alpha Adrenergic Blocking Agents
- alpha-Adrenergic Blockers
- Blockers, alpha-Adrenergic
- alpha Adrenergic Blockers
- alpha-Blockers, Adrenergic
- alpha Blockers, Adrenergic
- alpha-Adrenergic Receptor Blockaders
- Blockaders, alpha-Adrenergic Receptor
- Receptor Blockaders, alpha-Adrenergic
- alpha Adrenergic Receptor Blockaders
- Adrenergic alpha-Blockers
- Adrenergic alpha Blockers
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic alpha-Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic alpha-Antagonists".
This graph shows the total number of publications written about "Adrenergic alpha-Antagonists" by people in this website by year, and whether "Adrenergic alpha-Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenergic alpha-Antagonists" by people in Profiles.
-
Nuzhat SS, Osser DN. Chest pain in a young patient treated with prazosin for PTSD. Am J Psychiatry. 2009 May; 166(5):618-9.
-
Ellsworth P, Caldamone A. Pediatric voiding dysfunction: current evaluation and management. Urol Nurs. 2008 Aug; 28(4):249-57, 283; quiz 258.
-
Bruehl S, Chung OY, Diedrich L, Diedrich A, Robertson D. The relationship between resting blood pressure and acute pain sensitivity: effects of chronic pain and alpha-2 adrenergic blockade. J Behav Med. 2008 Feb; 31(1):71-80.
-
Copel L, Katz R, Blachar A, Sosna J, Sheiman RG. Clinical and duplex US assessment of effects of sildenafil on cavernosal arteries of the penis: comparison with intracavernosal injection of vasoactive agents--initial experience. Radiology. 2005 Dec; 237(3):986-91.
-
Moore TL, Schettler SP, Killiany RJ, Herndon JG, Luebke JI, Moss MB, Rosene DL. Cognitive impairment in aged rhesus monkeys associated with monoamine receptors in the prefrontal cortex. Behav Brain Res. 2005 May 28; 160(2):208-21.
-
Mazzeo RS, Dubay A, Kirsch J, Braun B, Butterfield GE, Rock PB, Wolfel EE, Zamudio S, Moore LG. Influence of alpha-adrenergic blockade on the catecholamine response to exercise at 4,300 meters. Metabolism. 2003 Nov; 52(11):1471-7.
-
Wilson TA, Foxall TL, Nicolosi RJ. Doxazosin, an alpha-1 antagonist, prevents further progression of the advanced atherosclerotic lesion in hypercholesterolemic hamsters. Metabolism. 2003 Oct; 52(10):1240-5.
-
Sarkar S, Tsai SW, Nguyen TT, Plevyak M, Padbury JF, Rubin LP. Inhibition of placental 11beta-hydroxysteroid dehydrogenase type 2 by catecholamines via alpha-adrenergic signaling. Am J Physiol Regul Integr Comp Physiol. 2001 Dec; 281(6):R1966-74.
-
ZhuGe R, Li S, Chen TH, Hsu WH. Alpha2-adrenergic receptor-mediated Ca2+ influx and release in porcine myometrial cells. Biol Reprod. 1997 May; 56(5):1343-50.
-
Kuchel GA, DuBeau CE, Resnick NM. Terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 1997 Jan 23; 336(4):293-4; author reply 294.